Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Parvin beta (PARVB) is an actin-binding adaptor protein of the parvin family, found at focal adhesions within the cytoplasm where it interacts with integrin-linked kinase (ILK), paxillin, alpha-actinin, and guanine nucleotide exchange factors. It plays a central role in coordinating integrin signaling, reorganizing the actin cytoskeleton, mediating cell adhesion and migration, regulating anchorage, and establishing cell polarity[1][2][5]. PARVB is also implicated in tumor suppression, with its downregulation enhancing oncogenic signaling and promoting tumor progression and metastasis in several carcinomas[1]. It is genetically associated with metabolic liver disease (notably nonalcoholic fatty liver disease) and participates in membrane repair in muscle and in response to bacterial effector proteins, highlighting roles beyond structural cytoskeletal support[1]. PARVB is not considered a typical drug target or receptor and currently has no known direct therapeutic ligands or drugs[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Parvin beta (PARVB).